Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer
暂无分享,去创建一个
P. Mantyh | T. Rosol | Patrick W Mantyh | J. Ghilardi | Molly A Sevcik | Thomas J Rosol | Molly A. Sevcik | Joseph R Ghilardi | Kyle G Halvorson | M. A. Sevcik | K. Halvorson | J. R. Ghilardi
[1] M. Vasko,et al. Prostaglandin-induced neuropeptide release from spinal cord. , 1995, Progress in brain research.
[2] E. Mccleskey,et al. Chemical mediators of pain due to tissue damage and ischemia. , 2000, Progress in brain research.
[3] K. Seibert,et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.
[4] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[5] P. Mantyh,et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. , 2005, Cancer research.
[6] P. Mantyh,et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization , 2005, Pain.
[7] P. Mantyh,et al. Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain , 2005, Experimental Neurology.
[8] T. Mak,et al. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. , 2001, Cancer research.
[9] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[10] A. Lipton,et al. Oral bisphosphonates , 2000, Cancer.
[11] S. Santavirta,et al. Innervation of bone from healthy and arthritic rats by substance P and calcitonin gene related peptide containing sensory fibers. , 1992, The Journal of rheumatology.
[12] W. Daughaday,et al. Tumor secretion of growth factors. , 1991, Endocrinology and metabolism clinics of North America.
[13] S. Mercadante,et al. Breakthrough pain in cancer patients: pathophysiology and treatment. , 1998, Cancer treatment reviews.
[14] Steven F. Maier,et al. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states , 1995, Pain.
[15] G. Davar. Endothelin-1 and metastatic cancer pain. , 2001, Pain medicine.
[16] S. Mercadante. Problems of long-term spinal opioid treatment in advanced cancer patients , 1999, Pain.
[17] M. Kress,et al. Involvement of the Proinflammatory Cytokines Tumor Necrosis Factor-α, IL-1β, and IL-6 But Not IL-8 in the Development of Heat Hyperalgesia: Effects on Heat-Evoked Calcitonin Gene-Related Peptide Release from Rat Skin , 2000, The Journal of Neuroscience.
[18] Paul J. Williams,et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. , 2001, Cancer research.
[19] F. Sinicrope,et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. , 1999, Cancer research.
[20] P. Yarnold,et al. IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. , 2000, The Journal of urology.
[21] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[22] C. Stein,et al. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor in vivo , 1992, Neuropeptides.
[23] L. King,et al. Role of epidermal growth factor in carcinogenesis. , 1986, Cancer research.
[24] N. Davies,et al. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. , 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[25] R. Yezierski,et al. The role of neuroinflammation and neuroimmune activation in persistent pain , 2001, Pain.
[26] K. Foley. Misconceptions and controversies regarding the use of opioids in cancer pain. , 1995, Anti-cancer drugs.
[27] J. Nelson,et al. The role of endothelin‐1 and endothelin receptor antagonists in prostate cancer , 2000, BJU international.
[28] A. Cohn. Bone tumors. , 1978, Orthopedics.
[29] L. Mendell,et al. Characteristics of nerve growth factor induced hyperalgesia in adult rats: dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activation , 1996, PAIN®.
[30] J. Body. Tumor bone diseases and osteoporosis in cancer patients : pathophysiology, diagnosis, and therapy , 2000 .
[31] S. Adami,et al. New Bisphosphonates in the Treatment of Bone Diseases , 1999, Drugs & aging.
[32] P. Mantyh,et al. Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain , 1999, The Journal of Neuroscience.
[33] L. Terenius,et al. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.
[34] L. Raisz,et al. Prostaglandins and bone metabolism , 2020, Principles of Bone Biology.
[35] O. S. Nielsen,et al. Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Nelson,et al. Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.
[37] S. Landis,et al. Developmental Changes in the Transmitter Properties of Sympathetic Neurons That Innervate the Periosteum , 2000, The Journal of Neuroscience.
[38] M. Lazdunski,et al. How Nerve Growth Factor Drives Physiological and Inflammatory Expressions of Acid-sensing Ion Channel 3 in Sensory Neurons* , 2003, Journal of Biological Chemistry.
[39] Atsushi Tokunaga,et al. Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury , 2000, Molecular and Cellular Neuroscience.
[40] H. Gould,et al. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain , 2000, Brain Research.
[41] D. Julius,et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.
[42] N. Carruthers,et al. Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain , 2005, The Journal of Neuroscience.
[43] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[44] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[45] R MELZACK,et al. The perception of pain. , 1961, Scientific American.
[46] P. Yarnold,et al. IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITIS , 2000 .
[47] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[48] G. Mundy,et al. Bone remodeling and its disorders , 1999 .
[49] S. Fan,et al. Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Mantyh,et al. Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. , 2005, The journal of pain : official journal of the American Pain Society.
[51] Platelet-derived growth factor in human malignancy. , 1992, BioFactors.
[52] M. Carducci,et al. Endothelin receptor antagonists in the treatment of prostate cancer. , 2003, Seminars in oncology.
[53] L. Djouhri,et al. Association of somatic action potential shape with sensory receptive properties in guinea‐pig dorsal root ganglion neurones , 1998, The Journal of physiology.
[54] R. Roberts,et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. , 2001, Neoplasia.
[55] T. Yoneda,et al. Factors regulating the growth of metastatic cancer in bone. , 1999, Endocrine-related cancer.
[56] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[57] R. Kinscherf,et al. Modulating apoptosis: current applications and prospects for future drug development. , 1999, Current medicinal chemistry.
[58] M. Weber,et al. Documentation of severe pain, opioid doses, and opioid-related side effects in outpatients with cancer: a retrospective study. , 1999, Journal of pain and symptom management.
[59] P. Mantyh,et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. , 2002, Cancer research.
[60] W. Tetzlaff,et al. Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[61] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[62] C. Galasko,et al. Diagnosis of skeletal metastases and assessment of response to treatment. , 1995, Clinical orthopaedics and related research.
[63] Clifford J. Woolf,et al. Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.
[64] J. Mönkkönen,et al. Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.
[65] P. Mantyh,et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons , 2000, Neuroscience.
[66] A. Basbaum,et al. Molecular mechanisms of nociception , 2001, Nature.
[67] T. Guise. Parathyroid hormone‐related protein and bone metastases , 1997, Cancer.
[68] M. T. Brewer,et al. Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia , 1995, Brain Research.
[69] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[70] C. Gentry,et al. Regulation and function of spinal and peripheral neuronal B1 bradykinin receptors in inflammatory mechanical hyperalgesia , 2003, Pain.
[71] A. Bjurholm. Neuroendocrine peptides in bone , 2004, International Orthopaedics.
[72] 園下 将大. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc[Δ716] knockout mice , 2004 .
[73] W. Ichikawa,et al. Depth of invasion parallels increased cyclooxygenase‐2 levels in patients with gastric carcinoma , 2001, Cancer.
[74] M. T. Brewer,et al. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. , 1995, Brain research.
[75] S. Felten,et al. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. , 1996, Acta histochemica.
[76] J. Bonica,et al. Management of cancer pain. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[77] R. Couture,et al. Kinin receptors in pain and inflammation. , 2001, European journal of pharmacology.
[78] S. McMahon,et al. NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury , 2004, The European journal of neuroscience.
[79] B F Boyce,et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.
[80] S. Woolf. Patient Safety Is Not Enough: Targeting Quality Improvements To Optimize the Health of the Population , 2004, Annals of Internal Medicine.
[81] S. Mercadante. Malignant bone pain: pathophysiology and treatment , 1996, Pain.
[82] A. Basbaum,et al. The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.
[83] M. Horton,et al. Integrins and Other Cell Surface Attachment Molecules of Bone Cells , 2002 .
[84] Qingyuan Yang,et al. Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer , 2001, International journal of cancer.
[85] F. Fulfaro,et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials , 1998, Pain.
[86] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[87] E. Kalso,et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.
[88] J. Body. Metastatic bone disease: clinical and therapeutic aspects. , 1992, Bone.
[89] J. Griffiths. Are cancer cells acidic? , 1991, British Journal of Cancer.
[90] V. Steele,et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. , 2000, Cancer research.
[91] S. McMahon,et al. Nerve growth factor induces P2X3 expression in sensory neurons , 2001, Journal of neurochemistry.
[92] R. Beauchamp,et al. TGF‐β and colorectal carcinogenesis , 2001 .
[93] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[94] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[95] R. Radinsky. Growth factors and their receptors in metastasis. , 1991, Seminars in cancer biology.
[96] M. Lazdunski,et al. The Acid-sensitive Ionic Channel Subunit ASIC and the Mammalian Degenerin MDEG Form a Heteromultimeric H+-gated Na+ Channel with Novel Properties* , 1997, The Journal of Biological Chemistry.
[97] Michael A. Kuskowski,et al. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis , 2004, Pain.
[98] H. Thoenen,et al. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection , 1987, The Journal of cell biology.
[99] N. Cherny. New strategies in opioid therapy for cancer pain. , 2000, The Journal of oncology management : the official journal of the American College of Oncology Administrators.
[100] P. Mantyh,et al. Endothelin and the tumorigenic component of bone cancer pain , 2004, Neuroscience.
[101] X. Ortiz-González,et al. An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats , 1998, Neuroreport.
[102] S. Maier,et al. Implications of immune-to-brain communication for sickness and pain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[103] T. Martin,et al. Therapeutic approaches to bone diseases. , 2000, Science.
[104] R E Coleman,et al. Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.
[105] G. Hans,et al. Behavioral signs of acute pain produced by application of endothelin‐1 to rat sciatic nerve , 1998, Neuroreport.
[106] J. Morrow,et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.
[107] P. Mantyh,et al. Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.
[108] R. Beauchamp,et al. TGF-beta and colorectal carcinogenesis. , 2001, Microscopy research and technique.
[109] J. Nelson,et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] S. Perkins,et al. Review of Cellular Mechanisms of Tumor Osteolysis , 2000, Clinical orthopaedics and related research.
[111] R. DuBois,et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. , 1996, Gastroenterology.
[112] P. Mantyh,et al. Expression and Localization of Endothelin Receptors: Implications for the Involvement of Peripheral Glia in Nociception , 2001, The Journal of Neuroscience.
[113] I. Taylor,et al. Endothelin-1 and tumour development. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[114] Atsushi Tokunaga,et al. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats , 2003, Pain.
[115] C. Woolf,et al. p38 MAPK Activation by NGF in Primary Sensory Neurons after Inflammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia , 2002, Neuron.
[116] I. Taylor,et al. Angiogenesis in cancer: the role of endothelin-1. , 1999, Annals of the Royal College of Surgeons of England.
[117] Silverman Bj. Platelet-derived growth factor in human malignancy. , 1992 .
[118] M. Schultzberg,et al. Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.
[119] Paul J. Williams,et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma , 2000, Cancer.